4 found
Order:
  1. Against Permitted Exploitation in Developing World Research Agreements.Danielle M. Wenner - 2015 - Developing World Bioethics 16 (1):36-44.
    This paper examines the moral force of exploitation in developing world research agreements. Taking for granted that some clinical research which is conducted in the developing world but funded by developed world sponsors is exploitative, it asks whether a third party would be morally justified in enforcing limits on research agreements in order to ensure more fair and less exploitative outcomes. This question is particularly relevant when such exploitative transactions are entered into voluntarily by all relevant parties, and both research (...)
    Download  
     
    Export citation  
     
    Bookmark   4 citations  
  2. Patient-Funded Trials: Opportunity or Liability?Danielle M. Wenner, Alex John London & Jonathan Kimmelman - 2015 - Cell Stem Cell 17 (2):135-137.
    Patient-funded trials are gaining traction as a means of accelerating clinical translation. However, such trials sidestep mechanisms that promote rigor, relevance, efficiency, and fairness. We recommend that funding bodies or research institutions establish mechanisms for merit review of patient-funded trials, and we offer some basic criteria for evaluating PFT protocols.
    Download  
     
    Export citation  
     
    Bookmark   3 citations  
  3. Conflicts among Multinational Ethical and Scientific Standards for Clinical Trials of Therapeutic Interventions.Jacob M. Kolman, Nelda P. Wray, Carol M. Ashton, Danielle M. Wenner, Anna F. Jarman & Baruch A. Brody - 2012 - Journal of Law, Medicine and Ethics 40 (1):99-121.
    There has been a growing concern over establishing norms that ensure the ethically acceptable and scientifically sound conduct of clinical trials. Among the leading norms internationally are the World Medical Association's Declaration of Helsinki, guidelines by the Council for International Organizations of Medical Sciences, the International Conference on Harmonization's standards for industry, and the CONSORT group's reporting norms, in addition to the influential U.S. Federal Common Rule, Food and Drug Administration's body of regulations, and information sheets by the Department of (...)
    Download  
     
    Export citation  
     
    Bookmark   2 citations  
  4. Diversion Effects, Incentive Effects, and the Goals of Research Ethics Promulgations.Danielle M. Wenner - 2015 - Journal of Law and the Biosciences.
    Download  
     
    Export citation  
     
    Bookmark